References
- Sattar N., McCarey D. W., Capell H., McInnes I. B. Explaining how ‘high‐grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957–63
- del Rincon I. D., Williams K., Stern M. P., Freeman G. L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737–45
- Raitakari O. T., Celermajer D. S. Flow‐mediated dilatation. Br J Clin Pharmacol 2000; 50: 397–404
- Salonen J. T., Salonen R. Ultrasound B‐mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87((3 Suppl))II56–65
- Hurlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti‐tumor necrosis factor‐alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184–7
- Van Doornu S., McColl G., Wicks I. P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1428–32
- Gonzalez‐Juanatey C., Llorca J., Garcia‐Porrua C., Martin J., Gonzalez‐Gay M. A. Effect of anti‐tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150–3
- Del Porto F., Lagana B., Lai S., Nofroni I., Tinti F., Vitale M., et al. Response to anti‐tumour necrosis factor alpha blockade is associated with reduction of carotid intima–media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111–15
- Jacobsson L. T., Turesson C., Gulfe A., Kapetanovic M. C., Petersson I. F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213–18
- Prevoo M. L., van 't Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L. Modified disease activity scores that include twenty‐eight‐joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
- van Gestel A. M., Haagsma C. J., van Riel P. L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845–50
- Skalidis E. I., Zacharis E. A., Tsetis D. K., Pagonidis K., Chlouverakis G., Yarmenitis S., et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol 2007; 99: 1258–62
- Dixon W. G., Watson K. D., Lunt M., Hyrich K. L., Silman A. J., Symmons D. P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti‐tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905–12
- Gonzalez‐Juanatey C., Testa A., Garcia‐Castelo A., Garcia‐Porrua C., Llorca J., Gonzalez‐Gay M. A. Active but transient improvement of endothelial function in rheumatoid arthritispatients undergoing long‐term treatment with anti‐tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447–50
- Irace C., Mancuso G., Fiaschi E., Madia A., Sesti G., Gnasso A. Effect of anti‐TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177: 113–18